Oticon

Oticon, a cornerstone of the Danish Demant Group, is a mission-driven medical device company with a 120-year legacy of innovating in hearing care. Its core strategy is built on the BrainHearing™ paradigm, which focuses on supporting the brain's natural listening processes rather than merely amplifying sound, a differentiator supported by its own independent research facility. The company achieves global scale through a vast, professional-led distribution network across 130 countries, commercializing a mature portfolio of AI-enabled hearing aids and accessories designed to mitigate the broader health risks associated with hearing loss.

BrainHearing™ platform, a paradigm that focuses on supporting the brain's natural listening processes using AI-powered Deep Neural Network (DNN) technology and multi-sensor systems to deliver a full, balanced soundscape.

Oticon competes in an oligopolistic global market dominated by large players like Sonova (Phonak), WS Audiology (Widex, Signia), and GN Group. Its key differentiators are the BrainHearing™ philosophy, strong brand heritage among professionals, and backing by the integrated Demant Group. It also faces emerging competition from consumer electronics companies in the OTC/mild loss segment.